National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Sufentanil (Zalviso®)

Sufentanil (Zalviso®) is indicated for the management of acute moderate to severe post-operative pain in adult patients.

NCPE Assessment Process Complete
Rapid review received 14/03/2016
Rapid review completed 22/03/2016
Rapid Review outcome Full Pharmacoeconomic Evaluation Recommended.
Full pharmacoeconomic assessment commissioned by HSE 16/08/2017
Pre-submission consultation with applicant 24/05/2017
Submission received from applicant 31/10/2017
Preliminary review sent to applicant 15/06/2018
HTA assessment discontinued The assessment of sufentanil (Zalviso®)  has been discontinued as the company has made a decision not to commercialise sufentanil in Ireland. 27/06/2018